Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies.
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Rivoceranib (Primary)
- Indications Breast cancer; Cervical cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer
- Focus Therapeutic Use
- 14 Feb 2018 Status changed from recruiting to completed.
- 28 Jan 2018 Planned End Date changed from 30 Jun 2018 to 28 Jan 2018.
- 03 Jan 2018 New trial record